Tesamorelin closes out Batch 1 because it is the growth-hormone-axis peptide with
the strongest regulatory and trial record — a useful reference point for
evaluating the others.
Chemical identity & structure.
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). It
is based on the full 44-amino-acid GHRH sequence, stabilized by the addition of
a trans-3-hexenoyl group at the N-terminus, which protects it from rapid
enzymatic degradation. It is a longer peptide than the GRF(1-29)-based analogs
such as CJC-1295.
Mechanism of action.
Tesamorelin is a GHRH-receptor agonist. It acts on the pituitary to stimulate
the release of growth hormone, raising GH and downstream IGF-1 in a manner that
preserves the body's pulsatile release pattern and regulatory feedback. Because
it works upstream, it is mechanistically distinct from administering hGH
directly.
Key research findings.
Tesamorelin was studied specifically for **excess visceral (abdominal) adipose
tissue in people with HIV-associated lipodystrophy**, and the Phase 3 trials
documented reductions in visceral fat. The trials also characterized its effects
on IGF-1 and its side-effect profile.
The research / citation base.
Tesamorelin is FDA-approved (brand name Egrifta) for its specific HIV-
lipodystrophy indication, supported by published Phase 3 trials. That makes it
one of the few GH-axis peptides in this library with a genuine regulatory-grade
human evidence base. Uses outside the approved indication are not supported by
that same level of evidence.
Human clinical trial data
In the pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials by Falutz et al. (2010), 806 ART-treated HIV patients with excess abdominal fat were randomized 2:1 to receive tesamorelin or placebo for a 26-week primary phase, followed by a 26-week safety extension (PubMed). At week 26, visceral adipose tissue decreased significantly in the tesamorelin-treated patients versus placebo (treatment effect, -15.4%) (PubMed).
Quality & sourcing notes.
Tesamorelin is a longer peptide, so a credible COA should confirm the full
sequence and N-terminal modification by mass spectrometry and report HPLC
purity. As with the other GH-axis peptides, confirm the COA describes
tesamorelin specifically and not a cheaper GRF analog.
*Research-use note: Educational summary of published research. Tesamorelin is a
prescription drug; this monograph is research context only and is not medical
advice.*